enoxaparin


Also found in: Dictionary, Wikipedia.

enoxaparin

 [e-nok″sah-par´in]
a low molecular weight heparin, used as the sodium salt to prevent pulmonary embolism and deep venous thrombosis following hip or knee replacement or high-risk abdominal surgery; administered subcutaneously as the sodium salt. It is also used together with warfarin in the treatment of deep venous thrombosis and together with aspirin in the prevention of coronary thrombosis associated with unstable angina or certain kinds of myocardial infarction.

enoxaparin

(ē-noks'ă-par-in),
A low-molecular-weight heparin.

enoxaparin

Lovenox® Vascular disease An LMW heparin anticoagulant used to prevent DVT, venous TE in Pts with acute medical disease, and to prevent ischemic complications of unstable angina and non-Q-wave MIs Adverse events Hemorrhage. See Deep vein thrombosis, Low-molecular-weight heparin.

enoxaparin

An anticoagulation drug used to prevent blood clots forming in the veins after surgery or to treat formed clots. It has been found superior to treatment with unfractionated heparin in patients on fibrinolysis for ST-elevation myocardial infarction but is associated with uncreased major bleeding episodes. A brand name is Clexane.
References in periodicals archive ?
Browse 44 Market Data Tables and 39 Figures spread through 218 Pages and in-depth TOC on "Low Molecular Weight Heparin Market, by Drug (Enoxaparin, Dalteparin, Nadroparin, Bemiparin, Tinzaparin, and Others), by Packaging (Multi-vials and Prefilled Syringes), by Application (Deep Vein Thrombosis, Acute Coronary Syndrome (ACS), Pulmonary Embolism, and Atrial Fibrillation), by End Use (Hospitals (Private and Public), Clinics, and Home), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Global Forecast to 2026"
The results showed that while both types of blood thinners prevented clots, 80 percent of patients receiving enoxaparin had minor bleeding during surgery, which correlated with theETP measurement.
Enoxaparin, a low-molecular-weight heparin, has anticoagulant and antithrombotic effects during PCI with no need of repeatedly monitoring ACT due to its longer half-life (3.5-4.5 h).
Conclusion: Low-molecular-weight heparin (enoxaparin) is safe for use in conjunction with indwelling epidural catheter if appropriate interval is provided for catheter insertion and removal.
We retrospectively analysed our data for short term outcome of efficacy and safety with use of enoxaparin as procedural anticoagulant.
The thicker subcutaneous tissue (>25 mm) and larger surface area of the abdominal wall are believed to reduce the risk of extravasation of enoxaparin (Avsar & Kasikci, 2013).
They were randomly assigned to receive one daily subcutaneous injection of 40 mg enoxaparin or placebo until 35 weeks' gestation.
Preparation of Chitosan-PCL Nanoparticles with Enoxaparin. Nanoparticles were prepared with a biodegradable polymer PCL (Aldrich) and coated with the natural polymer chitosan (105 g/mol/~81% acetylation, Polymar).
In this study, the model of glucocorticoid-associated ONFH was established in rabbits and we used combined treatment with an anticoagulant (enoxaparin) and a vasodilator (EGb 761), which prevented the development of glucocorticoid-associated ONFH more effectively than either treatment alone in rabbits.
Enoxaparin, low molecular weight heparins(LMWH), isused for the treatment and prophylaxis of thrombosis.
Another important finding was that excessive uterine bleeding was more than twice as common among women taking rivaroxaban as among those taking enoxaparin plus vitamin K antagonists.